JP5680407B2 - 新規ｘ連鎖性筋疾患に関連するｆｈｌ１変異 - Google Patents

新規ｘ連鎖性筋疾患に関連するｆｈｌ１変異 Download PDF

Info

Publication number
JP5680407B2
JP5680407B2 JP2010510620A JP2010510620A JP5680407B2 JP 5680407 B2 JP5680407 B2 JP 5680407B2 JP 2010510620 A JP2010510620 A JP 2010510620A JP 2010510620 A JP2010510620 A JP 2010510620A JP 5680407 B2 JP5680407 B2 JP 5680407B2
Authority
JP
Japan
Prior art keywords
protein
fhl
amino acid
nucleic acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010510620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010528630A (ja
JP2010528630A5 (https=
Inventor
ビンセント，ジョーン，ビー．
ヴィンドパッシンガー，クリスチャン
クヴァスホトフ，ステファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre for Addiction and Mental Health
Original Assignee
Centre for Addiction and Mental Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre for Addiction and Mental Health filed Critical Centre for Addiction and Mental Health
Publication of JP2010528630A publication Critical patent/JP2010528630A/ja
Publication of JP2010528630A5 publication Critical patent/JP2010528630A5/ja
Application granted granted Critical
Publication of JP5680407B2 publication Critical patent/JP5680407B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2878—Muscular dystrophy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010510620A 2007-06-04 2008-06-04 新規ｘ連鎖性筋疾患に関連するｆｈｌ１変異 Active JP5680407B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93325107P 2007-06-04 2007-06-04
US60/933,251 2007-06-04
PCT/CA2008/001062 WO2008148193A1 (en) 2007-06-04 2008-06-04 Fhl1 mutations associated with novel x-linked muscular myopathies

Publications (3)

Publication Number Publication Date
JP2010528630A JP2010528630A (ja) 2010-08-26
JP2010528630A5 JP2010528630A5 (https=) 2013-11-07
JP5680407B2 true JP5680407B2 (ja) 2015-03-04

Family

ID=40093102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010510620A Active JP5680407B2 (ja) 2007-06-04 2008-06-04 新規ｘ連鎖性筋疾患に関連するｆｈｌ１変異

Country Status (4)

Country Link
US (3) US8580502B2 (https=)
JP (1) JP5680407B2 (https=)
CA (1) CA2688678C (https=)
WO (1) WO2008148193A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011033034A1 (en) * 2009-09-17 2011-03-24 Roche Diagnostics Gmbh Multimarker panel for left ventricular hypertrophy
EP3220948B1 (en) * 2014-11-17 2019-09-18 Stiftelsen Vectis Novel autoantigen in idiopathic inflammatory myopathies
CN105779464B (zh) * 2014-12-26 2019-06-14 深圳华大生命科学研究院 分离的编码fhl1突变体的核酸及其应用
JP6799863B2 (ja) * 2015-12-01 2020-12-16 学校法人 川崎学園 心疾患または筋疾患の診断薬
JP6719779B2 (ja) 2017-07-27 2020-07-08 白石工業株式会社 炭酸カルシウムを含む食品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239060A (en) * 1986-07-25 1993-08-24 The Children's Medical Center Corporation Muscular dystrophy protein, dystrophin
WO2003072827A1 (en) * 2001-10-31 2003-09-04 Children's Hospital Medical Center Method for diagnosis and treatment of rheumatoid arthritis
WO2005113812A2 (en) * 2004-04-23 2005-12-01 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents

Also Published As

Publication number Publication date
US20160002309A1 (en) 2016-01-07
JP2010528630A (ja) 2010-08-26
US9150923B2 (en) 2015-10-06
US20100240039A1 (en) 2010-09-23
WO2008148193A1 (en) 2008-12-11
CA2688678A1 (en) 2008-12-11
US20140162259A1 (en) 2014-06-12
CA2688678C (en) 2023-03-14
US8580502B2 (en) 2013-11-12
US9617320B2 (en) 2017-04-11

Similar Documents

Publication Publication Date Title
Windpassinger et al. An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1
Olson et al. Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy
Gruver et al. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta–cardiac myosin heavy chain mutation
Perrot et al. Prevalence of cardiac beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy
Dalakas et al. Progressive skeletal myopathy, a phenotypic variant of desmin myopathy associated with desmin mutations
US9617320B2 (en) Nucleic acids encoding FHL1 mutations associated with novel X-linked muscular myopathies and methods of screening a subject
US20160258022A1 (en) Methods for Assessing Risk for Cardiac Dysrythmia in a Human Subject
Summers et al. Recent developments in the diagnosis of Marfan syndrome and related disorders
EP4534695A1 (en) Genetic markers for diagnosis or prognosis prediction of degenerative temporomandibular joint osteoarthritis and use thereof
Al-Mahdawi et al. Identification of a mutation in the beta cardiac myosin heavy chain gene in a family with hypertrophic cardiomyopathy.
KR101542907B1 (ko) Ｃｍｔ에 대한 원인 유전자로서 ｐｌｅｋｈｇ5 및 이를 이용한 상기 질병의 진단 방법
JP5695719B2 (ja) ジュベール症候群に関連するｃｃ２ｄ２ａ遺伝子変異及びその同定診断法
JP4706193B2 (ja) マルファン症候群の分析のためのプローブの使用、スクリーニング方法およびキット
KR101289134B1 (ko) 유전성 샤르코-마리-투스 말초신경병증의 cmt4b3 아형에 대한 원인 유전자로서의 sbf1(mtmr5) 돌연변이 유전자 및 이를 이용한 상기 질병의 진단방법 및 진단용 조성물
KR101274276B1 (ko) 말초신경병, 근육병, 청각장애 및 쉰목소리의 복합 증상의 원인 유전자로서 ｍｙｈ１４ 및 이를 이용한 상기 복합 증상의 진단방법 및 진단키트
Massie et al. Mitochondrial myopathy due to novel missense mutation in the cytochrome c oxidase 1 gene
CN101622361A (zh) 用于心律不齐的风险管理的遗传标记物
Kabaeva Genetic analysis in hypertrophic cardiomyopathy
US20120219944A1 (en) Myh14 as causative gene responsible for complex phenotype of peripheral neuropathy, myopathy, hearing loss and hoarseness, and diagnostic method and kit for the complex phenotype using the same
CN113652422A (zh) Jup基因突变体及其应用
Chrestian et al. CONGENITAL MYOPATHIES 1–NEMALINE: P. 26 A new intronic mutation in nebulin myopathy
Lee et al. CONGENITAL MYOPATHIES 1–NEMALINE: P. 25 Autosomal recessive congenital myopathy with splicing mutation (c. 21522+ 3A> G) of NEB gene
van Kleef et al. CONGENITAL MYOPATHIES 1–NEMALINE: P. 24 Respiratory muscle weakness in nemaline myopathy patients
Sframeli Clinical and molecular characterization of patients affected by congenital muscular dystrophies using next generation sequencing strategies
Naddaf et al. Hereditary myopathies with early respiratory failure

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130716

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130816

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130913

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150107

R150 Certificate of patent or registration of utility model

Ref document number: 5680407

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250